[Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes].
Incorporación de resultados informados por pacientes con psoriasis y dermatitis atópica en las consultas de atención farmacéutica y dermatología: herramienta que mejora la calidad asistencial y resultados en salud.
Atopic dermatitis
Dermatitis atópica
Health outcomes
Patient satisfaction
Patient-reported outcomes
Psoriasis
Resultados en salud
Resultados reportados por los pacientes
Satisfacción del paciente
Journal
Journal of healthcare quality research
ISSN: 2603-6479
Titre abrégé: J Healthc Qual Res
Pays: Spain
ID NLM: 101735273
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
03
10
2022
revised:
17
01
2023
accepted:
04
10
2023
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
2
11
2023
Statut:
aheadofprint
Résumé
Patient-reported outcomes (PROs) provide subjective information about their disease, treatment, and quality of life. To introduce a new system of work coordinated between pharmacists and dermatologists, based on the collection and analysis of PROs to assess its clinical impact as well as patients satisfaction. A prospective single-centre observational study was conducted under clinical conditions and included adult patients diagnosed with psoriasis (PS) and atopic dermatitis (AD) between April-2021 and February-2022. Pharmacists and dermatologists agreed on this systematic work. A REDCap® database was designed to facilitate data collection and the subsequent analysis. A total of 288 and 41 patients with PS and AD, respectively, were included. Those who started treatment showed significant improvement with a decrease in PROs and clinical parameters (p < 0.001). The pharmacist made 168 and 7 recommendations to dermatologists for PS and AD patients, respectively, of which 66.07% and 57.1% were accepted. The most common recommendations were «consult with rheumatologist» (20.83%), «extend drug regimen» (19.64%) and «consider change in treatment» (11.90%). Adverse events were reported in 55 and 17 patients with PS and AD, respectively. Of 103 patients, 75% were «very satisfied» and 20% «satisfied» with the system. This new working system helps to evaluate the short and long-term effectiveness of treatments and also to identify adverse events, alarm symptoms and co-morbidities in order to optimize therapies. Collaboration between pharmacists and dermatologists reduces decision-making time and patients appreciate better clinical care leading to higher patient satisfaction.
Identifiants
pubmed: 37919175
pii: S2603-6479(23)00062-3
doi: 10.1016/j.jhqr.2023.10.004
pii:
doi:
Types de publication
English Abstract
Journal Article
Langues
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 FECA. Publicado por Elsevier España, S.L.U. All rights reserved.